CROI 19 (Retrovirus) 2012

19th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 March 2012, Seattle

HIV and the brain: longitudinal results from CHARTER and other studies

Systolic blood pressure and risk of myocardial infarction in HIV infection

Risk of non-AIDS defining malignancies and immune suppression

Renal impairment in the D:A:D study

Early data for rilpivirine long acting formulation supports further investigation for PrEP

Hormonal contraception: HIV transmission and progression rates

Darunavir use during pregnancy

19th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 March 2012

Cure research takes centre stage: proof of concept for activating the latent reservoir

Quad fixed-dose integrase combination: phase 3 studies at week 48

Dolutegravir studies continue to show promise

Tenofovir prodrug: 10 day monotherapy study sets dose at 25 mg for easier coformulation

Paediatric formulations of ARVs: including an exciting new class

Lower malaria risk in children receiving lopinavir/ritonavir-based compared to NNRTI-based ART

High prevalence of d4T-associated lipodystrophy including lipoatrophy in children

Lopinavir/ritonavir monotherapy in children

Stopping treatment after early ART in infants

PrEP: PK modeling of daily TDF/FTC (Truvada) provides close to 100% protection against HIV infection

Risk of HIV reinfection may be similar to risk of initial HIV infection

Case report: homozygous CCR5 delta-32 protection overcome by infection with X4 virus

No association between atazanavir and MI or stroke in D:A:D study

Hepatitis C coinfection studies

Herpes Zoster vaccine safe and effective in HIV positive people

High dose flu vaccine improves antibody responses in HIV positive people